Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant + Zimberelimab in Advanced Malignancies
NCT03629756Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Jul 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of etrumadenant in renal cell carcinoma (RCC) and prostate cancer (PCa) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Percentage of participants with Adverse Events and Percentage of participants who experience a Dose Limiting Toxicity at 28 days. Started Jul 2018; status: completed.
02
Drugs
etrumadenant
03
Conditions
renal cell carcinoma (RCC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03629756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629756.